Matrix Metalloproteinase 2 as a New Marker for Diagnosis of Chronic Kidney Disease

Alallam, Ahmed Salah Amin; Mohamed, Ahmed Saad Abdelhalim; Hassaan, Mohamed Mohamed Mohamed; Metwally, Ola Badr; Abdelghany, Lamiaa Raafat Elsayed; Abdelaziem, Osama Mosbah

doi:10.21608/ejhm.2022.223320

Matrix Metalloproteinase 2 as a New Marker for Diagnosis of Chronic Kidney Disease

Authors

10.21608/ejhm.2022.223320

Abstract

Background: Chronic kidney disease (CKD) is highly prevalent, irreversible, progressive decrease in renal function. Matrix metalloproteinases (MMPs) have an important role in tissue remodelling by regulating cell death, morphogenesis and wound healing activity. Objective: The aim was to assess the diagnostic value of matrix metalloproteinase 2 as a new marker in chronic kidney disease.
Patients and Methods: this study was conducted on (108) individuals who were divided into 3 groups of matching age and sex. Group I (Control group): 36 healthy individuals with normal kidney functions. Group II (CKD group): (stage 1-4) 36 subjects with eGFR between 15-89 ml/min/1.73m². Group III (ESRD group): 36 subjects who were under regular hemodialysis for more than 3 months.
Results: There was statistically non-significant difference between the studied groups regarding serum cholesterol. There was statistically significant difference between the studied groups regarding MMP-2. On comparing each two individual groups using Tukey post hoc test for MMP-2, the difference was significant between each two individual groups (MMP-2 was lower in Group I followed by Group II then Group III). The best cutoff of MMP2 in diagnosis of ESRD was ≥0.69615 to <0.78155 with area under curve 0.766, sensitivity 77.8%, specificity 63.9%, positive predictive value (PPV) 68.3%, negative predictive value (NPV) 74.2% and accuracy 70.8%.
Conclusion: There was significantly increased levels of MMP-2 in CKD with more increase in ESRD patients. MMP-2 could be used as a marker in diagnosis of CKD.

Keywords